Anshul Maheshwari Sells 18,542 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 18,542 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $20.15, for a total value of $373,621.30. Following the sale, the chief financial officer directly owned 185,231 shares in the company, valued at approximately $3,732,404.65. This represents a 9.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Tuesday, November 25th, Anshul Maheshwari sold 100 shares of SiBone stock. The shares were sold at an average price of $20.00, for a total transaction of $2,000.00.
• On Friday, November 21st, Anshul Maheshwari sold 1,200 shares of SiBone stock. The stock was sold at an average price of $20.01, for a total transaction of $24,012.00.
• On Monday, November 17th, Anshul Maheshwari sold 3,460 shares of SiBone stock. The stock was sold at an average price of $17.43, for a total transaction of $60,307.80.
• On Tuesday, November 11th, Anshul Maheshwari sold 2,601 shares of SiBone stock. The shares were sold at an average price of $18.33, for a total transaction of $47,676.33.
• On Thursday, October 2nd, Anshul Maheshwari sold 3,311 shares of SiBone stock. The shares were sold at an average price of $14.20, for a total transaction of $47,016.20.

SiBone Stock Performance

NASDAQ SIBN traded up $0.13 during trading hours on Friday, reaching $20.38. The company’s stock had a trading volume of 711,205 shares, compared to its average volume of 452,878. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21. The business has a 50-day simple moving average of $17.31 and a 200 day simple moving average of $16.86. SiBone has a 52 week low of $12.49 and a 52 week high of $20.80. The stock has a market cap of $884.31 million, a PE ratio of -39.96 and a beta of 0.76.

SiBone (NASDAQ:SIBN) last posted its earnings results on Monday, November 10th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. The company had revenue of $48.66 million during the quarter, compared to analyst estimates of $46.67 million. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%. Equities research analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.

Institutional Trading of SiBone

A number of institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of SiBone by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after acquiring an additional 1,053 shares during the period. Tudor Investment Corp ET AL boosted its stake in SiBone by 0.8% during the 3rd quarter. Tudor Investment Corp ET AL now owns 258,032 shares of the company’s stock valued at $3,798,000 after purchasing an additional 1,968 shares in the last quarter. Rhumbline Advisers increased its position in shares of SiBone by 3.6% during the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock valued at $838,000 after purchasing an additional 2,100 shares during the period. Franklin Resources Inc. raised its stake in shares of SiBone by 8.3% in the 3rd quarter. Franklin Resources Inc. now owns 29,018 shares of the company’s stock worth $427,000 after buying an additional 2,228 shares in the last quarter. Finally, EntryPoint Capital LLC lifted its holdings in shares of SiBone by 21.5% in the first quarter. EntryPoint Capital LLC now owns 14,787 shares of the company’s stock valued at $207,000 after buying an additional 2,613 shares during the period. 98.11% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on SIBN. Truist Financial raised their target price on SiBone from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday. Morgan Stanley increased their price objective on shares of SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Needham & Company LLC lifted their price objective on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday. Canaccord Genuity Group boosted their target price on shares of SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of SiBone in a research note on Monday. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, SiBone has an average rating of “Moderate Buy” and a consensus price target of $25.00.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.